Results 21 to 30 of about 4,093 (216)

Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children

Frontiers in Pediatrics, 2023
BackgroundAngiopoietin-like 3 (ANGPTL3) is a secretory glycoprotein. It has been demonstrated that ANGPTL3 level was upregulated in minimal change nephrotic syndrome (MCNS) kidney tissues.
Fujie Wen, Junchao Liu, Rufeng Dai, Sha Hong, Baowei Ji, Jiaojiao Liu, Jun Zhang, Xinli Han, Qianying Lv, Jialu Liu, Qian Shen, Hong Xu   +11 more
doaj   +1 more source

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

Journal of Clinical Medicine, 2022
Familial hypercholesterolemia (FH) is an inherited disorder. The level of low-density lipoprotein cholesterol (LDL-C) in patients with homozygous FH can be twice as high as that in patients with heterozygous FH. The inhibition of ANGPTL3 shows an important therapeutic approach in reducing LDL-C and triglycerides (TG) levels and, thus, is a potentially ...
Bożena Sosnowska, Weronika Adach, Stanisław Surma, Robert S. Rosenson, Maciej Banach   +4 more
openaire   +3 more sources

ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer [PDF]

Cancer Res Commun
Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima, H. Imazeki, Kai Tsugaru, Naoki Takahashi, Takeshi Kawakami, Yusuke Amanuma, Takeru Wakatsuki, Naohiro Okano, Yukiya Narita, Y. Yamamoto, Rika Kizawa, Kei Muro, Narikazu Boku   +14 more
openalex   +2 more sources

Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice

Journal of Lipid Research, 2021
Supported by an abundance of experimental and genetic evidence, angiopoietin-like protein 3 (ANGPTL3) has emerged as a promising therapeutic target for cardiovascular disease. ANGPTL3 is primarily produced by the liver and is a potent modulator of plasma
Thomas A. Bell, III, Mingxia Liu, Aaron J. Donner, Richard G. Lee, Adam E. Mullick, Rosanne M. Crooke   +5 more
doaj   +1 more source

ANGPTL3 Deficiency and Risk of Hepatic Steatosis

Circulation, 2023
BACKGROUND: ANGPTL3 (angiopoietin-like 3) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of ANGPTL3, reported a dose-dependent increase in hepatic fat.
Laura D’Erasmo, Michele Di Martino, Thomas Neufeld, Tyler J. Fraum, Chul Joo Kang, Kendall H. Burks, Alessia Di Costanzo, Ilenia Minicocci, Simone Bini, Marianna Maranghi, Giovanni Pigna, Giancarlo Labbadia, Jie Zheng, Davide Fierro, Anna Montali, Fabrizio Ceci, Carlo Catalano, Nicholas O. Davidson, Giuseppe Lucisano, Antonio Nicolucci, Marcello Arca, Nathan O. Stitziel   +21 more
openaire   +3 more sources

ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis

Current Atherosclerosis Reports, 2022
Elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride-rich lipoproteins (TRLs) or remnants are important risk factors for the development of atherosclerotic cardiovascular disease (ASCVD). The ongoing challenge of not being able to achieve recommended LDL-C targets despite maximally tolerated lipid-lowering therapy (LLT) has led to the ...
Farzahna Mohamed, Brett S. Mansfield, Frederick J. Raal   +2 more
openaire   +2 more sources

Decoding the role of angiopoietin-like protein 4/8 complex–mediated plasmin generation in the regulation of LPL activity

Journal of Lipid Research, 2023
After feeding, adipose tissue lipoprotein lipase (LPL) activity should be maximized, therefore the potent LPL-inhibitory activity of angiopoietin-like protein 4 (ANGPTL4) must be blocked by ANGPTL8 through formation of ANGPTL4/8 complexes.
Yan Q. Chen, Eugene Y. Zhen, Anna M. Russell, Mariam Ehsani, Robert W. Siegel, Yuewei Qian, Robert J. Konrad   +6 more
doaj   +1 more source

A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice

Frontiers in Immunology, 2022
IntroductionThe pathogenic mechanisms of diabetic nephropathy (DN) include podocyte injury, inflammatory responses and metabolic disorders. Although the antagonism of Angiopoietin-like protein 3 (ANGPTL3) can alleviate proteinuria symptoms by inhibiting ...
Qianqian Ma, Xiaozhi Hu, Fangyu Liu, Zhonglian Cao, Lei Han, Kaicheng Zhou, Yu Bai, Yuting Zhang, Yanyang Nan, Qianying Lv, Jia Rao, Tao Wu, Xue Yang, Haidong He, Dianwen Ju, Dianwen Ju, Hong Xu   +16 more
doaj   +1 more source

The Potential of ANGPTL8 Antagonism to Simultaneously Reduce Triglyceride and Increase HDL-Cholesterol Plasma Levels

Frontiers in Cardiovascular Medicine, 2021
Elevated triglyceride (TG) and reduced high-density lipoprotein-cholesterol (HDL-C) plasma levels are risk factors for atherosclerosis and cardiovascular disease.
Ren Zhang
doaj   +1 more source

Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi[S]

Journal of Lipid Research, 2020
Angiopoietin-like protein 3 (ANGPTL3) inhibits lipid clearance and is a promising target for managing cardiovascular disease. Here we investigated the effects of a high-sugar (high-fructose) diet on circulating ANGPTL3 concentrations in rhesus macaques ...
Andrew A. Butler, James L. Graham, Kimber L. Stanhope, So Wong, Sarah King, Andrew A. Bremer, Ronald M. Krauss, James Hamilton, Peter J. Havel   +8 more
doaj   +1 more source